Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS hosts the first Southern African Young Scientists Summer Programme
2012-11-26

The University of the Free State is to host the first Southern African Young Scientists Summer Programme (SA-YSSP) from 1 December 2012 to 28 February 2013. 

This will form part of an annual three-month education, academic training and research capacity-building programme jointly organised by the National Research Foundation (NRF), the Department of Science and Technology (DST), and the International Institute for Applied Systems Analysis (IIASA), based in Austria.
 
The NRF, as the National Member Organisation (NMO), in collaboration with DST, has developed a novel and innovative initiative with IIASA to establish the SA-YSSP. This programme was officially launched by the Minister of Science and Technology during November 2011.
 
IIASA is an international research organisation that conducts policy-oriented scientific research in the three global problem areas of energy and climate change, food and water and poverty and equity (www.iiasa.ac.at). South Africa’s engagements with IIASA, and specifically with regard to the SA-YSSP, relate primarily to the DST’s Ten-Year Innovation Plan.
 
Aligned with the YSSP model that is presented by IIASA in Austria annually, the SA-YSSP offers scientific seminars covering themes in both the social and natural sciences. These seminars often have policy dimensions and aim to broaden the participants’ perspectives and strengthen their analytical and modelling skills, further enriching a demanding academic and research programme (www.ufs.ac.za/sa-yssp).
 
Keynote lectures are to be delivered by national and international leaders in their respective research fields, partly drawn from IIASA’s widespread network of alumni and collaborators, as well as from the NRF’s extensive international networks of excellence.
 
The programme is to be enhanced with specific field trips and cultural and heritage excursions that will involve networking with locally based research programmes. Supervisory teams of both IIASA and South African experts will guide a cohort of competitively selected South African and international advanced Ph.D candidates.
 
The programme will be opened on 2 December 2012 at the Centenary Complex by the Minister of Science and Technology, Mr Derek Hanekom, the Director/CEO of IIASA, Prof Pavel Kabat and the Vice-Chancellor and Rector of the UFS, Prof Jonathan Jansen. They will be joined by a number of Nobel Prize Laureates and luminaries representing the government, the diplomatic sector and Higher Education.
 
The programme is directed by a multidisciplinary team at the UFS that includes:
Prof Aldo Stroebel and Prof Neil Roos (Co-Directors)
Prof André Roodt (Dean of SA-YSSP)
Prof Martin Ntwaeaborwa and Dr Henriëtte van den Berg (Deputy-Deans of SA-YSSP)
Dr Priscilla Mensah and Dr Sonja Loots (Strategic Managers)

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept